​

Dianthus Therapeutics (DNTH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

DNTH Stock Forecast

Dianthus Therapeutics (DNTH) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $109.56, with a high of $145.00 and a low of $55.00. This represents a 25.37% increase from the last price of $87.39.

- $30 $60 $90 $120 $150 High: $145 Avg: $109.56 Low: $55 Last Closed Price: $87.39

DNTH Stock Rating

Dianthus Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 1 Strong Buy (10.00%), 9 Buy (90.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 9 1 Strong Sell Sell Hold Buy Strong Buy

DNTH Price Target Upside V Benchmarks

TypeNameUpside
StockDianthus Therapeutics25.37%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts11015
Avg Price Target$98.00$111.10$96.20
Last Closing Price$87.39$87.39$87.39
Upside/Downside12.14%27.13%10.08%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-15---15
Mar, 26113---14
Feb, 26113---14
Jan, 26113---14
Dec, 25113---14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 08, 2026Andy ChenWolfe Research$98.00$87.4812.03%12.14%
Mar 09, 2026Maury RaycroftUBS$98.00$79.2323.69%12.14%
Mar 09, 2026Maury RaycroftJefferies$98.00$79.2323.69%12.14%
Mar 09, 2026Trevor AllredOppenheimer$145.00$80.8879.28%65.92%
Mar 09, 2026Alex ThompsonStifel Nicolaus$120.00$80.6048.88%37.32%
Feb 11, 2026Wedbush$55.00$49.7010.66%-37.06%
Jan 29, 2026UBS$125.00$53.23134.83%43.04%
Jan 08, 2026Truist Financial$63.00$38.0965.40%-27.91%
Nov 06, 2025Trevor AllredOppenheimer$62.00$36.4670.05%-29.05%
Oct 14, 2025Danielle BrillTruist Financial$56.00$34.4262.70%-35.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 08, 2026Wolfe ResearchOutperforminitialise
Mar 16, 2026William BlairOutperformOutperformhold
Mar 10, 2026Raymond JamesOutperformStrong Buyupgrade
Mar 09, 2026JefferiesBuyBuyhold
Mar 09, 2026Cowen & Co.BuyBuyhold
Mar 09, 2026OppenheimerOutperformOutperformhold
Feb 11, 2026WedbushOutperformOutperformhold
Jan 29, 2026OppenheimerOutperformOutperformhold
Nov 06, 2025OppenheimerOutperformOutperformhold
Sep 12, 2025WedbushOutperformOutperformhold

Financial Forecast

EPS Forecast

$-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.45$-2.55----
Avg Forecast$-5.53$-2.56$-3.45$-3.94$-4.16$-3.87
High Forecast$-3.77$-2.10$-2.59$-2.80$-2.62$-2.30
Low Forecast$-7.29$-3.00$-4.58$-5.25$-6.71$-6.35
Surprise %52.80%-0.39%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.83M$6.24M$2.04M---
Avg Forecast$2.46M$5.54M$3.71M$4.11M$19.11M$75.36M
High Forecast$2.65M$6.72M$5.54M$6.13M$28.53M$112.53M
Low Forecast$2.12M$4.65M$2.55M$2.82M$13.13M$51.80M
Surprise %14.80%12.46%-45.13%---

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-43.55M$-84.97M$-162.34M---
Avg Forecast$-28.50M$-13.15M$-18.47M$-20.76M$-24.05M$-19.93M
High Forecast$-19.43M$-10.82M$-13.35M$-14.45M$-13.52M$-11.83M
Low Forecast$-37.57M$-15.48M$-23.59M$-27.08M$-34.57M$-32.70M
Surprise %52.83%546.21%778.77%---

DNTH Forecast FAQ

Is Dianthus Therapeutics stock a buy?

Dianthus Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 9 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Dianthus Therapeutics is a favorable investment for most analysts.

What is Dianthus Therapeutics's price target?

Dianthus Therapeutics's price target, set by 10 Wall Street analysts, averages $109.56 over the next 12 months. The price target range spans from $55 at the low end to $145 at the high end, suggesting a potential 25.37% change from the previous closing price of $87.39.

How does Dianthus Therapeutics stock forecast compare to its benchmarks?

Dianthus Therapeutics's stock forecast shows a 25.37% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Dianthus Therapeutics over the past three months?

  • April 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 7.14% Strong Buy, 92.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 7.14% Strong Buy, 92.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Dianthus Therapeutics’s EPS forecast?

Dianthus Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3.94, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $-4.16 in 2027, and $-3.87 in 2028.

What is Dianthus Therapeutics’s revenue forecast?

Dianthus Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $4.11M, reflecting a 101.71% increase from the reported $2.04M in 2025. The forecast for 2027 is $19.11M, and $75.36M for 2028.

What is Dianthus Therapeutics’s net income forecast?

Dianthus Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-20.762M, representing a -87.21% decrease from the reported $-162M in 2025. Projections indicate $-24.045M in 2027, and $-19.929M in 2028.